Susana Banerjee, Professor in Women’s Cancers at The Institute of Cancer Research, shared on X:
“Phase 2 RAMP201 (ENGOTov60/GTG-UK/GOG3052) trial leading to FDA accelerated approval avumetinib and defactinib now published in Journal of Clinical Oncology, Verastem Oncology. First approved therapy for low grade serous ovarian cancer. Thanks all.”
Read this insightful article about Ovarian Cancer:
